Asia Pacific
This content originates from Baxter International Inc. prior to the company establishing its chronic kidney care and acute therapies businesses into one standalone company, Vantive. This content might contain references to products/brands/persons/services that are not applicable or relevant at the present time. Please contact us in case of any questions.
Baxter announces support for finalization of core component of the Advancing American Kidney Health initiative
Patient Access
- End-Stage Renal Disease Treatment Choices Model brings greater access to home dialysis for patients with kidney failure
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today issued this statement:
We are pleased that the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, a core component of the Administration's Advancing American Kidney Health Initiative (AAKHI), has been finalized. We believe patients with kidney failure deserve greater access to home dialysis so they can make the best treatment choice for themselves and their families. Baxter applauds this groundbreaking effort and remains committed to working closely with healthcare providers to increase home dialysis adoption.
About Vantive
Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. Today, patients across more than 100 countries around the world interact with Vantive’s people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility, efficiency and therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.